statement
博拓生物在2026年第三季度業績説明會上表示,公司堅持創新驅動,以POCT快速診斷為主業。
A statement by 博拓生物. Statements are as reported by the cited publishers — not verified by DecisionGateway.
博拓生物在2026年第三季度業績説明會上表示,公司堅持創新驅動,以POCT快速診斷為主業
Discussion
Related claims
The statements were made at the company's Q3 2026 results briefing.鐵龍物流 · statement公司提升POCT產品綜合競爭力。博拓生物 · commitmentTAT Technologies published record results for the third quarter and the nine months of 2026, with growth in revenues, profit margins and EBITDA.תאת טכנולוגיות · statementAt the investor day, management highlighted AI-driven drug discovery (AIDD) as an emerging structural growth driver.管理層 · statementThe embodied intelligence industry platform established by 晉拓股份, 南大開發 and 宇樹科技 has officially launched.post author · statementThis is the first case clinically demonstrating the strategic advantage IMVT-1402 has over Batoclimab.하나증권 제약/바이오 김선아 · statement
More claims by 博拓生物
公司開闢長期潛在增長曲線。prediction公司通過設立產業投資平台參股投資或併購、參與產業基金等方式探索腦機接口、AI醫療等新興方向。commitment公司在醫療前沿領域積極佈局。statement公司提升POCT產品綜合競爭力。commitment公司推進微流控熒光檢測平台高端、高質量的微流控芯片檢測試劑開發。commitment
All claims by 博拓生物